✦ LIBER ✦

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

✍ Scribed by Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher

Book ID: 117785312
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 236 KB
Volume: 11
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(10)70054-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of neoadjuvant pertu

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

✍ Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; M 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 217 KB

Short-term androgen suppression and radi

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

✍ Denham, James W; Joseph, David; Lamb, David S; Spry, Nigel A; Duchesne, Gillian; 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 542 KB

Effects of the addition of gemcitabine,

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

✍ Earl, Helena M; Vallier, Anne-Laure; Hiller, Louise; Fenwick, Nicola; Young, Jen 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 349 KB